[
    "on of novel coronaviruses (amikacin variants)</p>The drug efficacy test was performed using the drug assembly prepared in example 3, lot 3 (using the spray device of example 1).</p>1. Cell lines and viruses:</p>VeroE6 cells. Novel coronavirus Omikou variant (BA.1.1.529) titre TCID <sub>50</sub> = 10 <sup>-5.5</sup> 100. Mu.L, stored at-80 \u2103.</p>2. Experimental protocol:</p>(1) Cell control, virus control and drug component groups with different concentrations are set.</p>(2) The liquids prepared in lot 3, steps (1) and (2) of example 3 were diluted 2-fold, 4-fold, 8-fold, 16-fold, 32-fold, 64-fold, respectively, and placed into the pharmaceutical assembly of the present application (using the spraying apparatus of example 1).</p>(3) The cell density was set at 2X 10 <sup>5 </sup> VeroE6 cell suspensions of cells/NL were plated in sterile 96 well plates with 100. Mu.L of each well at 37\u2103with 5% CO <sub>2</sub> Culture 24 h was performed in the ambient.</p>(4) Discarding culture supernatant, mixing the spray solution with 100 TCID <sub>50</sub> Mixing virus solution 1:1, incubating at 37deg.C for 2 hr, transferring the above mixed solution onto 96-well plate, mixing with 100 \u03bcl/well of 4 compound wells, incubating for 2 hr, removing supernatant, adding maintenance medium, mixing with 100 \u03bcl/well, and incubating for 3 days. Cytopathic effect (CPE) was observed and the experimental results were recorded, recording CPE. The recording results are shown in table 7 below:</p></p>(5) Half maximal Inhibitory Concentration (IC) was calculated using Reed-Nuench method or GraphPad PrisN5.0 <sub>50</sub> )\u3002</p>3. Experimental results:</p>the experimental results show that: the medicine component of the application has inhibiting effect on proliferation of novel coronavirus omnikom variant in cells and IC <sub>50</sub> 9.286. The results are shown in table 8 below and in fig. 4:</p></p>experimental example 2: inhibition of influenza A H1N1 virus</p>The inhibition of influenza a H1N1 virus was evaluated using the pharmaceutical kit prepared in example 3, lot 3 (using the spray device of example 1).</p>1. Cell lines and viruses:</p>NDCK, hep-2, veroE6 cells, NDCK cells were expanded in 90NL dnan medium+1nl penicillin, streptomycin stock (100X) +10nl foetal calf serum, 0.01% EDTA-0.25% pancreatin.</p>Influenza a H1N1 virus PR8 strain. 99NL DNEN broth+1 NL antibiotic+150. Mu.L TPCK-pancreatin (stock solution concentration 1 Ng/NL) was prepared for use.</p>2. Experimental protocol:</p>(1) The spray liquid sprayed after pressing the spraying device in the medicine component is mixed with fresh H1N1 virus stock solution 1:1 for 1 hour. After 1 hour, the solution was diluted by a factor of 10 to 7 dilutions to 10 <sup>-7</sup> . The virus control group was mixed with fresh H1N1 virus stock 1:1 with sterile water for 1 hour. After 1 hour, the solution was diluted by a factor of 10 to 7 dilutions to 10 <sup>-7</sup> \u3002</p>(2) 96-well plate monolayer cell plates containing"
]